Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 22563 | 321 | 44.8 | 95% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | ERK5 | Author keyword | 67 | 61% | 22% | 70 |
| 2 | MEK5 | Author keyword | 16 | 64% | 5% | 16 |
| 3 | EXTRACELLULAR SIGNAL REGULATED KINASE 5 ERK5 | Author keyword | 12 | 75% | 3% | 9 |
| 4 | EXTRACELLULAR SIGNAL REGULATED KINASE 5 | Author keyword | 9 | 64% | 3% | 9 |
| 5 | MEKK2 | Author keyword | 8 | 62% | 2% | 8 |
| 6 | BMK1 | Author keyword | 7 | 64% | 2% | 7 |
| 7 | EXTRACELLULAR SIGNAL REGULATED PROTEIN KINASE 5 | Author keyword | 4 | 67% | 1% | 4 |
| 8 | BIG MITOGEN ACTIVATED PROTEIN KINASE 1 BMK1 | Author keyword | 3 | 100% | 1% | 3 |
| 9 | BIG MITOGEN ACTIVATED PROTEIN KINASE | Author keyword | 2 | 67% | 1% | 2 |
| 10 | BIG MITOGEN ACTIVATED PROTEIN KINASE 1 | Author keyword | 2 | 67% | 1% | 2 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | ERK5 | 57 | 71% | 14% | 46 |
| 2 | BMK1 ERK5 | 52 | 80% | 10% | 32 |
| 3 | SIGNAL REGULATED KINASE 5 | 46 | 74% | 11% | 34 |
| 4 | KINASE 1 BMK1 | 31 | 92% | 4% | 12 |
| 5 | BMK1 | 27 | 92% | 3% | 11 |
| 6 | 1 BMK1 | 25 | 77% | 5% | 17 |
| 7 | MAMMALIAN MAP KINASE | 21 | 71% | 5% | 17 |
| 8 | ERK5 BMK1 | 17 | 75% | 4% | 12 |
| 9 | REGULATED KINASE 5 | 15 | 82% | 3% | 9 |
| 10 | PROTEIN KINASE 1 BMK1 | 14 | 53% | 6% | 18 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| ERK5: Structure, regulation and function | 2012 | 26 | 125 | 55% |
| Regulation of cellular functions by the ERK5 signalling pathway | 2006 | 145 | 72 | 71% |
| MEK5/ERK5 pathway: The first fifteen years | 2012 | 28 | 110 | 49% |
| MAPK signalling: ERK5 versus ERK1/2 | 2006 | 187 | 70 | 49% |
| The Signaling Pathway Leading to Extracellular Signal-Regulated Kinase 5 (ERK5) Activation via G-Proteins and ERK5-Dependent Neurotrophic Effects | 2010 | 21 | 41 | 59% |
| ERK 5/MAPK pathway has a major role in 1 alpha,25-(OH)(2) vitamin D-3-induced terminal differentiation of myeloid leukemia cells | 2014 | 4 | 12 | 42% |
| Role of the BMK1/ERK5 signaling pathway: lessons from knockout mice | 2004 | 93 | 60 | 62% |
| Role of extracellular signal regulated kinase 5 in neuronal survival | 2004 | 57 | 36 | 50% |
| Counting on mitogen-activated protein kinases - ERKs 3, 4, 5, 6, 7 and 8 | 2004 | 77 | 102 | 41% |
| ERK and cell death: ERK1/2 in neuronal death | 2010 | 67 | 69 | 7% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | NWCRF | 1 | 50% | 0.6% | 2 |
| 2 | AGING ALZHEIMERS DIS FOCUSED OU | 1 | 50% | 0.3% | 1 |
| 3 | BIOMFG TECHNOL ENTERPRISE BRITE | 1 | 50% | 0.3% | 1 |
| 4 | CARLOS INVEST 3 | 1 | 50% | 0.3% | 1 |
| 5 | FEDERATIF RECH 122 | 1 | 50% | 0.3% | 1 |
| 6 | HISTOL COMPARAT PATHOL | 1 | 50% | 0.3% | 1 |
| 7 | LOUISVILLE VET ADM MED | 1 | 50% | 0.3% | 1 |
| 8 | ORTHOPAED WARD 1 | 1 | 50% | 0.3% | 1 |
| 9 | SMI 301 | 1 | 50% | 0.3% | 1 |
| 10 | TOXICOL NUTR SCI | 1 | 50% | 0.3% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000202656 | MEF2C//MEF2//MEF2D |
| 2 | 0.0000190049 | KSR1//PEA 15//IST ENDOCRINOL ONCOL SPERIMENTALE GAETANO SALVA |
| 3 | 0.0000122288 | JNK//MKK4//JNK3 |
| 4 | 0.0000083632 | MK2//MAPKAP K2//MK5 |
| 5 | 0.0000080402 | METABOLIC MEMORY//HYPERGLYCEMIC MEMORY//EPIGEN PROFILING IL |
| 6 | 0.0000074434 | RAF//RAF 1//LEO JENKINS CANC |
| 7 | 0.0000069350 | CARDIAC MED SECT//NHLI CARDIAC MED//BIOMED SCI MOL PATHOL |
| 8 | 0.0000062567 | TPL2//TPL 2//TPL2 KINASE |
| 9 | 0.0000060712 | KLF6//KLF4//KRUPPEL LIKE FACTOR 4 |
| 10 | 0.0000056049 | COFFIN LOWRY SYNDROME//RSK2//SL0101 |